RayKnowChina Research Map
Shortlist0

Not yet recruitingStomach cancerPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07333573, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients must provide tumor tissue samples, with positive AXL and CD73 confirmed by immunohistochemical (IHC) staining at a central laboratory: AXL positivity rate ≥50% with staining intensity ≥++, and CD73 positivity rate ≥30% with staining intensity ≥+.

    Inclusion criterion 3

  3. More than 4 weeks since the last failed treatment, and any toxicities from previous treatments must have recovered to Grade ≤ 1.

    Inclusion criterion 7

  4. ECOG Performance Status score of ≤ 1.

    Inclusion criterion 4

  5. Hemoglobin (Hb) ≥ 90 g/L. 2. Absolute Neutrophil Count (ANC) ≥ 1.0 × 10\^9/L. 3. Absolute Lymphocyte Count ≥ 0.5 × 10\^9/L. 4. Platelet count ≥ 100 × 10\^9/L. 5. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN).

    Inclusion criterion 9

    Serum amylase and lipase ≤ 1.0 × ULN. 7. Total bilirubin ≤ 1.5 × ULN. 8. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula).

    Inclusion criterion 10

  6. At least one measurable lesion (≥ 1 cm).

    Inclusion criterion 6

  7. Active Hepatitis B (HBsAg positive with detectable HBV DNA), active Hepatitis C (HCV RNA positive), or HIV antibody positive.

    Exclusion criterion 14

    History of other malignant tumors within the past 3 years.

    Exclusion criterion 23

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07333573, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Aged 18 to 75 years, male or female.
  • Clinically judged as unresectable Stage IV gastric cancer that has progressed on or is intolerant to standard therapy, or patients who voluntarily forego standard therapy.
  • Patients must provide tumor tissue samples, with positive AXL and CD73 confirmed by immunohistochemical (IHC) staining at a central laboratory: AXL positivity rate ≥50% with staining intensity ≥++, and CD73 positivity rate ≥30% with staining intensity ≥+.
  • ECOG Performance Status score of ≤ 1.
  • Life expectancy of ≥ 3 months.
  • At least one measurable lesion (≥ 1 cm).
  • More than 4 weeks since the last failed treatment, and any toxicities from previous treatments must have recovered to Grade ≤ 1.
  • Adequate organ function and bone marrow reserve, as defined by the following laboratory values within a specified period before enrollment:
  • Hemoglobin (Hb) ≥ 90 g/L. 2. Absolute Neutrophil Count (ANC) ≥ 1.0 × 10\^9/L. 3. Absolute Lymphocyte Count ≥ 0.5 × 10\^9/L. 4. Platelet count ≥ 100 × 10\^9/L. 5. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN).
  • Serum amylase and lipase ≤ 1.0 × ULN. 7. Total bilirubin ≤ 1.5 × ULN. 8. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula).
  • Prothrombin Time (PT) or International Normalized Ratio (INR), and Partial Thromboplastin Time (PTT) < 1.5 × ULN. (Patients receiving warfarin or heparin anticoagulation therapy may be enrolled if no underlying abnormality in these parameters is suspected, but require close monitoring with at least weekly testing until INR is stable).
  • Adequate cardiac and pulmonary function. 10. Women of childbearing potential must have a negative pregnancy test within 7 days before treatment initiation. All subjects must agree to use effective contraception during the treatment period and for 1 year thereafter.
  • Voluntary signing of a written informed consent form, good compliance, and willingness to cooperate with follow-up.

Exclusion Criteria:

  • Active, known, or highly suspected autoimmune disease.
  • Patients with brain metastases who have active central nervous system symptoms. (Note: Patients with brain metastases who completed radiotherapy at least 3 months prior to enrollment and remain asymptomatic from CNS disease may be eligible).
  • Active, uncontrolled systemic infection.
  • Receiving high-dose corticosteroids (>10 mg/day of methylprednisolone or equivalent doses of other corticosteroids) or other immunosuppressive therapy within 14 days prior to enrollment.
  • History of severe allergy to other monoclonal antibodies.
  • Intolerance or allergy to the investigational drug.
  • History of interstitial lung disease.
  • Evidence of organ failure:
  • Cardiac: Class III or IV heart failure (per NYHA or other applicable criteria).
  • Hepatic: Class C liver function as per Child-Pugh score.
  • Renal: Renal failure or uremia stage.
  • Pulmonary: Symptoms of severe respiratory failure.
  • Neurological: Impaired consciousness.
  • Active Hepatitis B (HBsAg positive with detectable HBV DNA), active Hepatitis C (HCV RNA positive), or HIV antibody positive.
  • History of organ transplantation.
  • Active gastrointestinal bleeding, or history of gastrointestinal bleeding within the past month.
  • History of drug abuse, or psychological/psychiatric disorders that may compromise compliance with the study.
  • Any unstable condition or situation that may jeopardize the patient's safety or compliance in the study.
  • Thyroid dysfunction.
  • Prior treatment with any form of adoptive T-cell therapy.
  • Currently receiving anticoagulant or antiplatelet therapy.
  • Major surgery or significant trauma within 4 weeks prior to enrollment.
  • History of other malignant tumors within the past 3 years.
  • Judged by the investigator as unsuitable for cell therapy.

Quoted from ClinicalTrials.gov, NCT07333573, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07333573, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07333573